Affilogic is a biotech company developing a new class of affinity proteins: Nanofitins // Affilogic est une société de biotechnologie développant une nouvelle classe de protéines d'affinité: les Nanofitines Company Profile :
Affilogic is a biotech company, created in Nantes in 2010, developing a new class of affinity ligands, Nanofitins®, which are able to selectively bind many targets and have p
roven excellent tools for:
• Targeting (immunolocalization, in vivo neutralization): Therapeutic applications
• Detection (immunoassays, Western Blot): Diagnostic / Analytic applications
• Capture (affinity chromatography, protein removal): Bioprocessing applications
Nanofitins® constitute a robust and affordable alternative to antibodies :
- High affinity (down to picomolar as monomers)
- Excellent drugability (very stable & highly soluble),
- Better tissue penetration (20 x smaller than mAbs),
- Cost effective scale up (cheaper manufacturing process)…
Thanks to these competitive advantages, Nanofitin®-based drugs aim at overcoming antibodies limitations, in particular by allowing better tissue penetration and patient-friendly formulations. Products/Technology :
Affilogic is investigating with several industrial and academic partners therapeutic fields such as :
• Inflammation (oral administration, skin permeation)
• CNS (delivery through BBB)
• Ophthalmology (cornea penetration)
• Infectious diseases (targeting of antimicrobial agents)
• Oncology (Nanofitin-Drug-Conjugate). Partnering Opportunities :
Affilogic is looking for partners for custom generation of Nanofitins® as affinity ligands, co-development of affinity applications and early-stage drug development.
